TAFINLAR (dabrafenib) capsules

TAFINLAR is a brand-name prescription drug that’s FDA-approved to treat skin cancer, lung cancer, thyroid cancer, solid tumors. Brand Name: TAFINLAR (dabrafenib) capsules, for oral use Initial U.S. Approval: 2013

Home | (dabrafenib) capsules

TAFINLAR (dabrafenib) capsules Price In India and overseas
TAFINLAR (dabrafenib) capsules

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TAFINLAR (dabrafenib) capsules

Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.

TAFINLAR is a prescription medicine used:
• alone or in combination with a medicine called trametinib to treat a type of skin cancer called melanoma:
• in combination with trametinib, to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.
• in combination with trametinib to treat a type of lung cancer called non-small cell lung cancer (NSCLC):
• in combination with trametinib to treat a type of thyroid cancer called anaplastic thyroid cancer (ATC):
• in combination with trametinib to treat solid tumors in adults and children 6 years and older

Dabrafenib mesylate is a kinase inhibitor. Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.

Drug (Brand / Generic): TAFINLAR / dabrafenib capsules
Current Indications: skin cancer, lung cancer, thyroid cancer, solid tumors
Marketed by:: Novartis Pharmaceuticals Corporation
Approval Date: 2013

Available as (Form & Strength): Capsules: 50 mg, 75 mg

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.